The content on this site is intended for healthcare professionals only
Dr Jorge Cortes speaks to ecancer about the primary analysis from the OPTIC trial, a dose-ranging study of 3 starting doses of ponatinib.
Initially, he mentions the background of the trial. Dr Cortes then discusses the methodology and results of this trial. He says; results from this OPTIC primary analysis show a trend toward dose-dependent efficacy and safety and may provide a refined understanding of the ponatinib benefit: Risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic-phase chronic myeloid leukaemia (CP-CML).
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
